Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin (Q38155218)

29 August 2017

title

Evaluation of the pharmacokinetics and drug interactions of the two recently developed statins, rosuvastatin and pitavastatin (English)

1 reference

29 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

Miao Hu

1

1 reference

29 August 2017

Brian Tomlinson

series ordinal

2

1 reference

29 August 2017

language of work or name

Englisch

0 references

publication date

25 October 2013

1 reference

Expert Opinion on Drug Metabolism & Toxicology

29 August 2017

published in

1 reference

29 August 2017

volume

10

1 reference

29 August 2017

issue

1

1 reference

29 August 2017

page(s)

51-65

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Human skeletal muscle drug transporters determine local exposure and toxicity of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pitavastatin - pharmacological profile from early phase studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Comparative pharmacology of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Safety of statins: focus on clinical pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of fibrates on metabolism of statins in human hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Comparison of the safety, tolerability, and pharmacokinetic profile of a single oral dose of pitavastatin 4 mg in adult subjects with severe renal impairment not on hemodialysis versus healthy adult subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of renal failure on drug transport and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Ethnic differences in statin disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Comparison of the pharmacokinetics of pitavastatin by formulation and ethnic group: an open-label, single-dose, two-way crossover pharmacokinetic study in healthy Caucasian and Japanese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Differential effect of genetic variants of Na+-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Global analysis of genetic variation in SLCO1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Transporter pharmacogenetics and statin toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacogenetic analysis of lipid responses to rosuvastatin in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

OATP1B1 388A>G polymorphism and pharmacokinetics of pitavastatin in Chinese healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of grapefruit juice and SLCO1B1 388A>G polymorphism on the pharmacokinetics of pitavastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The ABCG2 transporter and its relations with the pharmacokinetics, drug interaction and lipid-lowering effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Impact of ABCC2, ABCG2 and SLCO1B1 polymorphisms on the pharmacokinetics of pitavastatin in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of polymorphisms in ABCG2, SLCO1B1, SLC10A1 and CYP2C9/19 on plasma concentrations of rosuvastatin and lipid response in Chinese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The safety of statins in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Statin drug interactions and related adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Statin safety and drug interactions: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Case report of exercise and statin-fibrate combination therapy-caused myopathy in a patient with metabolic syndrome: contradictions between the two main therapeutic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug safety evaluation of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pitavastatin: finding its place in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Statin-drug interactions: not a class effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug–drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effect of itraconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The effect of fluconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The effect of erythromycin on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetic interactions between statins and fibrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Myopathy with statin-fibrate combination therapy: clinical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effect of gemfibrozil on the metabolism of pitavastatin--determining the best animal model for human CYP and UGT activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Clinical pharmacokinetics of fluvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

A clinically significant interaction between warfarin and simvastatin is unique to carriers of the CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Drug-drug interaction between pitavastatin and various drugs via OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Pharmacokinetic interaction between pitavastatin and valsartan: a randomized, open-labeled crossover study in healthy male Korean volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Rosuvastatin: a risk-benefit assessment for intensive lipid lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

The clinical impact of pitavastatin: comparative studies with other statins on LDL-C and HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Risks associated with statin therapy: a systematic overview of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Statin-induced myotoxicity: pharmacokinetic differences among statins and the risk of rhabdomyolysis, with particular reference to pitavastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Ins and outs of the ABCG2 multidrug transporter: an update on in vitro functional assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Impact of cholesterol on ABC and SLC transporters expression and function and its role in disposition variability to lipid-lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

Differential Effect of Grapefruit Juice on Intestinal Absorption of Statins Due to Inhibition of Organic Anion Transporting Polypeptide and/or P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.2014.851667

10.1517/17425255.2014.851667

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference